Ken Griffin Oncolytics Biotech Inc Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding ONCY
# of Institutions
38Shares Held
1.41MCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY348KShares$358,7620.0% of portfolio
-
International Assets Investment Management, LLC Orlando, FL201KShares$207,4950.02% of portfolio
-
Goldman Sachs Group Inc New York, NY83.6KShares$86,1050.0% of portfolio
-
Commonwealth Equity Services, LLC62.8KShares$64,6460.0% of portfolio
-
Royal Bank Of Canada Toronto, A661KShares$62,8630.0% of portfolio
About ONCOLYTICS BIOTECH INC
- Ticker ONCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 57,867,400
- Market Cap $59.6M
- Description
- Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...